This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1gkd

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1gkd.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1gkd.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1gkd| PDB=1gkd | SCENE= }}
{{STRUCTURE_1gkd| PDB=1gkd | SCENE= }}
-
'''MMP9 ACTIVE SITE MUTANT-INHIBITOR COMPLEX'''
+
===MMP9 ACTIVE SITE MUTANT-INHIBITOR COMPLEX===
-
==Overview==
+
<!--
-
Matrix metalloproteinases (MMPs) and their inhibitors are important in connective tissue re-modelling in diseases of the cardiovascular system, such as atherosclerosis. Various members of the MMP family have been shown to be expressed in atherosclerotic lesions, but MMP9 is consistently seen in inflammatory atherosclerotic lesions. MMP9 over-expression is implicated in the vascular re-modelling events preceding plaque rupture (the most common cause of acute myocardial infarction). Reduced MMP9 activity, either by genetic manipulation or through pharmacological intervention, has an impact on ventricular re-modelling following infarction. MMP9 activity may therefore represent a key mechanism in the pathogenesis of heart failure. We have determined the crystal structure, at 2.3 A resolution, of the catalytic domain of human MMP9 bound to a peptidic reverse hydroxamate inhibitor as well as the complex of the same inhibitor bound to an active-site mutant (E402Q) at 2.1 A resolution. MMP9 adopts the typical MMP fold. The catalytic centre is composed of the active-site zinc ion, co-ordinated by three histidine residues (401, 405 and 411) and the essential glutamic acid residue (402). The main differences between the catalytic domains of various MMPs occur in the S1' subsite or selectivity pocket. The S1' specificity site in MMP9 is perhaps best described as a tunnel leading toward solvent, as in MMP2 and MMP13, as opposed to the smaller pocket found in fibroblast collagenase and matrilysin. The present structure enables us to aid the design of potent and specific inhibitors for this important cardiovascular disease target.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12051944}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12051944 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12051944}}
==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: Hydrolase]]
[[Category: Hydrolase]]
[[Category: Matrix metalloprotease]]
[[Category: Matrix metalloprotease]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 17:41:12 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 1 05:25:59 2008''

Revision as of 02:26, 1 July 2008

Image:1gkd.png

Template:STRUCTURE 1gkd

MMP9 ACTIVE SITE MUTANT-INHIBITOR COMPLEX

Template:ABSTRACT PUBMED 12051944

About this Structure

1GKD is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor., Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA, J Mol Biol. 2002 May 24;319(1):173-81. PMID:12051944

Page seeded by OCA on Tue Jul 1 05:25:59 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1gkd"
Personal tools